Table 4 -.
Univariate Kaplan-Meier log-rank analysis and multivariate Cox proportional hazards models for OS for RPS, TS, and all patients within cohort.
| OS | RPS | Multivariate HR (95% CI); P | TS | Multivariate HR (95% CI); P | All | Multivariate HR (95% CI); P |
|---|---|---|---|---|---|---|
| Factor | Univariate | Univariate | Univariate | |||
| Female gender | P = 0.11 | P = 0.27 | P = 0.09 | |||
| Age | P < 0.01 | 1.52 (1.04–2.22); P = 0.03 | P < 0.01 | 0.65 (0.29–1.45); P = 0.29 | P = 0.01 | 1.19 (0.86–1.65); P = 0.29 |
| Race | P = 0.81 | P = 0.27 | P = 0.73 | |||
| DM | P < 0.01 | 1.85 (1.14–2.99); P = 0.01 | P = 0.42 | P < 0.01 | 1.73 (1.56–2.58); P = 0.01 | |
| CAD | P = 0.10 | P = 0.48 | P = 0.08 | |||
| Smoking history | P = 0.40 | P = 0.01 | 2.65 (1.34–5.23); P < 0.01 | P = 0.52 | ||
| Prior radiation | P = 0.33 | P = 0.12 | P = 0.02 | 1.36 (0.79–2.35); P = 0.27 | ||
| Known genetic syndrome | P = 0.12 | P < 0.01 | 0.00 (0.00–>100); P = 0.96 | P = 0.04 | 0.00 (0.00–>100); P = 0.93 | |
| Sepsis | P < 0.01 | 4.99 (1.90–13.1); P < 0.01 | P < 0.01 | 0.00 (0.00–>100); P = 1.00 | P < 0.01 | 5.78 (2.23–14.89); P < 0.01 |
| Multifocal | P = 0.07 | P = 0.21 | P = 0.06 | |||
| Margin | P < 0.01 | P < 0.01 | P = 0.03 | |||
| R0 | Reference | Reference | Reference | |||
| R1 | 1.55 (1.00–2.41); P = 0.05 | 1.31 (0.71–2.41); P = 0.39 | 1.49 (1.06–2.09); P = 0.02 | |||
| R2 | 2.67 (1.45–4.94); P < 0.01 | 2.05 (0.2–21.04); P = 0.55 | 1.90 (1.04–3.50); P = 0.04 | |||
| Histology | P = 0.08 | P < 0.01 | P = 0.03 | |||
| UPS | Reference | Reference | Reference | |||
| Chondrosarcoma | 0.51 (0.14–1.88); P = 0.31 | 4.00 (1.41–11.32); P < 0.01 | ||||
| Leiomyosarcoma | 1.10 (0.37–3.32); P = 0.86 | 1.06 (0.61–1.83); P = 0.85 | ||||
| Liposarcoma | 0.72 (0.29–1.82); P = 0.49 | 0.77 (0.45–1.33); P = 0.35 | ||||
| Myxofibrosarcoma | 2.47 (0.62–9.77); P = 0.20 | 2.61 (0.76–9.01); P = 0.13 | ||||
| MPNST | 3.25 (0.90–11.81); P = 0.07 | 5.01 (1.48–17.00); P = 0.01 | ||||
| PNET | 0.94 (0.20–4.39); P = 0.94 | 0.93 (0.21–4.08); P = 0.93 | ||||
| Rhabdomyosarcoma | 0.00 (0.00–>100); P = 0.99 | 1.15 (0.14–9.60); P = 0.90 | ||||
| Angiosarcoma | 1.82 (0.60–5.54); P = 0.29 | 3.60 (1.30–9.95); P = 0.01 | ||||
| Sarcoma not otherwise specified | 0.78 (0.23–2.64); P = 0.69 | 1.89 (0.84–4.23); P = 0.13 | ||||
| Small round cell tumors | 1.54 (0.26–9.03); P = 0.63 | 4.39 (1.17–16.50); P = 0.03 | ||||
| Synovial sarcoma | 0.61 (0.24–1.55); P = 0.30 | 1.27 (0.61–2.66); P = 0.52 | ||||
| Other | 0.35 (0.15–0.72); P = 0.01 | 1.11 (0.57–2.17); P = 0.76 | ||||
| Grade—low versus high grade | P < 0.01 | 3.25 (1.75–6.05); P < 0.01 | P = 0.22 | P < 0.01 | 2.47 (1.55–3.95); P < 0.01 | |
| Tumor necrosis | P < 0.01 | 1.96 (1.12–3.43); P = 0.02 | P < 0.01 | 1.04 (0.15–0.72); P = 0.90 | P = 0.02 | 1.30 (0.88–1.91); P = 0.18 |
| Nodal status | P < 0.01 | 1.98 (1.01–3.89); P = 0.05 | P = 0.02 | 6.59 (0.82–52.99); P = 0.08 | P = 0.01 | 1.95 (1.03–3.68); P = 0.04 |
| Neoadjuvant | P = 0.89 | P = 0.06 | P = 0.78 | |||
| Adjuvant | P = 0.95 | P < 0.01 | 1.23 (0.54–2.79); P = 0.57 | P = 0.83 | ||
| Obesity | P = 0.58 | P < 0.01 | 0.99 (0.57–1.73); P = 0.62 | P = 0.51 | ||
| Size >20 cm | P = 0.41 | P = 0.89 | P = 0.65 | |||
| Elevated NLR | P = 0.04 | 1.06 (0.61–1.84); P = 0.83 | P = 0.58 | P = 0.23 | ||
| Elevated PLR | P = 0.02 | 1.07 (0.61–1.87); P = 0.82 | P = 0.46 | P = 0.09 |
HR = hazard ratio; PNET = primitive neuroectodermal tumor